Results of the Extraordinary General Meeting
On November 18, 2025, argenx SE (NASDAQ: ARGX), a prominent global immunology company dedicated to enhancing the lives of individuals with severe autoimmune diseases, convened an Extraordinary General Meeting of shareholders to address vital matters impacting the company.
Approval of the Remuneration Policy
A significant item on the agenda was the company's remuneration policy. This policy received endorsement from the shareholders, passing with a substantial majority of 95.67%. The voting turnout was notable, with 91.1% of the share capital represented. This clear approval reflects deep confidence from shareholders in the leadership's direction.
Significance of the Decision
The success of this vote is critical as it ensures that the remuneration policy aligns with the company’s strategic vision and growth objectives. By approving this policy, shareholders contribute to fostering an environment that attracts and retains top talent, which is essential for argenx’s continued innovation and success in the competitive healthcare sector.
Future Prospects for argenx
As one of the leading firms in the immunology field, argenx is making remarkable strides with its innovative treatments aimed at serious autoimmune diseases. The company has an impressive portfolio and is making significant investments in research and development to further enhance its offerings.
Immunology Innovation Program
The company engages in partnerships with leading academic researchers through its Immunology Innovation Program (IIP). This program aims to translate groundbreaking immunology research into novel antibody-based therapies, expanding argenx's therapeutic portfolio and optimizing patient outcomes.
Investor and Media Communication
For continuous updates on the company’s initiatives, voting results, and strategic direction, investors and media representatives are encouraged to stay connected through argenx’s official channels. This commitment to transparency is commendable and enhances stakeholder engagement.
Contact Information
Should you require further information, please reach out to the following contacts within the company:
Media Contact: Ben Petok (Bpetok@argenx.com)
Investor Relations: Alexandra Roy (aroy@argenx.com)
Frequently Asked Questions
What was the main outcome of argenx's Extraordinary General Meeting?
The main outcome was the approval of the company's remuneration policy, receiving 95.67% support from shareholders.
What percentage of shareholders participated in the vote?
A total of 91.1% of the share capital was represented during the vote.
How does the remuneration policy benefit argenx?
The remuneration policy is designed to attract and retain talent, supporting the company in its growth and innovation in the healthcare sector.
What initiatives does argenx focus on for innovation?
Argens focuses on its Immunology Innovation Program to translate academic research into new antibody-based therapies.
Who can I contact for more information regarding argenx?
For media inquiries, Ben Petok can be reached at Bpetok@argenx.com, and for investor relations, Alexandra Roy can be contacted at aroy@argenx.com.
